Study unveils the GDF1 signaling pathway’s role in mitigating the adverse effects of hearing loss on Alzheimer’s disease, spotlighting potential avenues for therapeutic development.
Study shows that individuals with generalized joint hypermobility have a 30% higher risk of not recovering from acute COVID-19, highlighting the need for tailored treatment
Share this article Image Credit: Shutterstock/Ground Picture Autologous chimeric antigen receptor (CAR) T-cell therapies have proven to be groundbreaking in the management of select hematologic
Study uncovers high pollution levels at new school sites in England, surpassing WHO guidelines, raising concerns about children’s health and the need for policy reforms
Share this article An illustration of the human body highlighting the pancreas. Image Credit: Magic mine Pancreatic ductal adenocarcinoma (PDAC), notorious for its resistance to
Study highlights the significant role of lactate in promoting cancer cachexia via activation of the adipose-specific G-protein-coupled receptor 81 (GPR81), suggesting new therapeutic targets for
Share this article An illustration of T cells attacking cancer cells. Image Credit: Shutterstock/Peddalanka Ramesh Babu During the 10th Annual Immuno-Oncology 360° (IO360) Conference on
WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis from nonpartisan
MindBio Therapeutics Corp. announced first dosing has begun in a Phase 2B randomised controlled clinical trial microdosing MB22001 in patients with Major Depressive Disorder. In
SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations